SAE-related costs lower with larotrectinib than with entrectinib

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      International Society for Pharmacoeconomics and Outcomes Research

    2. 2.

      2019 US dollars

    Reference

    1. Williamson T, et al. Economic Analysis of Inpatient Adverse Event-Related Expenditures in Metastatic Solid Tumor Patients Exposed to Larotrectinib or Entrectinib. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/98929

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    SAE-related costs lower with larotrectinib than with entrectinib. PharmacoEcon Outcomes News 855, 27 (2020). https://doi.org/10.1007/s40274-020-6892-4

    Download citation